Granulocyte-Macrophage Colony-Stimulating Factor Treatment Before Doxorubicin and Cyclophosphamide Chemotherapy Priming in Women With Early-Stage Breast Cancer
| Autor: | Nathan L. Kobrinsky, Preston D Steen, Mary S. Cheang, Diane E. Sjolander, Ralph Levitt |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Priming (immunology) Breast Neoplasms chemistry.chemical_compound Breast cancer Double-Blind Method Sargramostim Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Doxorubicin Aged Chemotherapy business.industry Granulocyte-Macrophage Colony-Stimulating Factor Middle Aged medicine.disease Nitrogen mustard Endocrinology Granulocyte macrophage colony-stimulating factor chemistry Female business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 17:3426-3430 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1999.17.11.3426 |
| Popis: | PURPOSE: To determine if inhibition of stem-cell activity induced by granulocyte-macrophage colony-stimulating factor ([GM-CSF]; Sargramostim; Immunex Corporation, Seattle, WA) withdrawal or priming protects hematopoietic stem cells from the cytotoxic effects of adjuvant chemotherapy for early-stage breast cancer. PATIENTS AND METHODS: Serial blood counts were performed in 20 women with early-stage breast cancer receiving four courses of cyclophosphamide and doxorubicin chemotherapy. By a double-blind, placebo-controlled, balanced randomization, subjects received GM-CSF priming on days 5 to 1 for courses 1 and 3 or courses 2 and 4. RESULTS: Compared with before priming, after priming the times to neutrophil nadir (12.8 ± 2.5 days v 14.8 ± 1.5 days, respectively; P = .0001) and platelet nadir (mean ± SD, 10.1 ± 1.9 days v 11.1 ± 2.2 days, P CONCLUSIONS: GM-CSF priming from days 5 to 1 before doxorubicin and cyclophosphamide chemotherapy was associated with an earlier neutrophil and platelet nadir. On day 16, a higher mean neutrophil count and a lower proportion of patients with severe ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|